BRAF mutations are detected in approximately 3% to 8% of patients with NSCLC. In contrast to melanoma, in which most BRAF mutations occur at the V600 codon, only approximately 35% of BRAF-mutant NSCLC tumors harbor V600 mutations.
Among the remaining cases, 60% to 70% present non-V600 mutations, primarily in exons 11 and 15. BRAF mutations are classified into three classes according to their kinase activity and their dependence on RAS activation.
Compared with class I (V600), patients with class II and class III mutations are associated with poorer clinical outcomes partly due to the lack of effective targeted therapeutic strategies.
Journal of Thoracic Oncology (JTO) published a clinical update in Oncology on 19 Jan 2026.
The item focuses on Biology and Clinical Management of Non-V600 BRAF Alterations in NSCLC.
Review the original article for the full source wording and details.